Thousand Oaks Biologics Achieves EU QP Declaration
Thousand Oaks Biologics has reached an important milestone with its antibody-drug conjugate (ADC) manufacturing site receiving the EU Qualified Person (QP) Declaration. This success follows a rigorous audit that confirmed the adherence of their quality management system and production capabilities to the strict EU Good Manufacturing Practice (GMP) standards. As a result, Thousand Oaks Biologics Shanghai is now recognized as one of the few contract development and manufacturing organizations (CDMOs) in China that can offer comprehensive international ADC services.
Details of the Audit and Certification
The comprehensive audit lasted five days and was conducted by a senior QP in the field. This rigorous evaluation aligned with EudraLex Volume 4 and pertinent PIC/S directives, ensuring that all facets of the manufacturing process were thoroughly inspected. The audit team reviewed quality and production management systems as well as equipment, material controls, packaging, and labeling processes. Particular attention was paid to critical elements like sterility assurance and data integrity.
Focus Areas During the Audit
During the evaluation, significant ADC manufacturing processes were scrutinized, including the upstream production of drug substances, downstream processing steps, the conjugation process, aseptic fill-finish, and quality control testing. The inspection team acknowledged the advanced facilities and robust quality management practices at Thousand Oaks Biologics Shanghai, concluding that the site successfully meets EU GMP regulations.
The Importance of the EU QP System
Established in 1975, the EU QP system has become a benchmark for global pharmaceutical quality assurance. The defined legal responsibilities for QPs in batch release serve as critical components in ensuring the integrity of pharmaceutical products. Thousand Oaks Biologics’ achievement reflects positively on Chinese CDMOs, showcasing their quality capabilities and paving the way for local ADC developers to enter international supply chains more seamlessly.
Competitive Edge in Biopharmaceuticals
This prestigious certification bolsters Thousand Oaks Biologics' competitive positioning within the international biopharmaceutical market. The company plans to leverage this achievement as a springboard for further advancements in its ADC technology platforms. These advancements will encompass conjugate screening, process development, purification, and enhancing analytical methods.
Future Prospects and Commitment to Quality
Moreover, Thousand Oaks Biologics aims to enhance its GMP-compliant manufacturing capacity for both clinical and commercial drug products. The commitment to the optimization of manufacturing processes, effective change management, and comprehensive product comparability studies demonstrates their dedication to international standards. By integrating high-quality services from initial research and development phases to commercial production, the company is devoted to facilitating the creation and distribution of groundbreaking medicines for patients across the globe.
Frequently Asked Questions
What does the EU QP Declaration signify?
The EU QP Declaration confirms that a pharmaceutical product meets the stringent EU Good Manufacturing Practice standards, ensuring quality and safety.
How does this certification impact Thousand Oaks Biologics?
This certification enhances the company's credibility and competitiveness in the global biopharmaceutical market, allowing them to expand their services internationally.
What areas were focused on during the audit?
Key areas included sterility assurance, quality control testing, material management, and the review of critical manufacturing steps.
What is the significance of the EU QP system?
The EU QP system serves as a global standard for pharmaceutical quality assurance, defining the responsibilities of qualified persons in ensuring product integrity.
What are the company's future plans following this achievement?
Thousand Oaks Biologics plans to enhance its ADC technology platforms, expand manufacturing capacity, and optimize processes to support drug development and delivery.
